Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Bone tumor burden is significantly lower and the number of bone metastases/mouse is significantly inhibited
InChi: InChI=1S/C47H56ClFN8O8/c1-54-42(59)16-15-37(46(54)61)57-45(60)32-11-9-12-38(43(32)47(57)62)64-25-8-6-4-3-5-7-18-50-41(58)17-20-56-23-21-55(22-24-56)19-10-26-65-40-28-33-36(29-39(40)63-2)51-30-52-44(33)53-31-13-14-35(49)34(48)27-31/h9
where it appears to block movement of Arp2 and Arp3 into their active conformation
PubMed Central PMCID: PMC3328245
Exposure of proliferating WS1 cells to MK-8776 S-isomer is associated with rapid
Ambrisentan 1267 Bone tumor burden is significantlyAmbrisentan, also known as BSF 208075 and LU 208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6 minute walk distance) compared with placebo in two double blind, multicenter trials (ARIES 1 and ARIES 2). Ambrisentan was approved by
US$ 1027.00
US$ 637.50
US$ 2991.50
US$ 1869.00
US$ 1234.50
US$ 497.50